<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOFETILIDE</span><br/>(do-fe-ti'lyde)<br/><span class="topboxtradename">Tikosyn<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class iii</span>; <span class="classification">potassium channel blocker</span><br/><b>Prototype: </b>Amiodarone HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mcg, 250 mcg, 500 mcg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Class III antiarrhythmic agent that prolongs the cardiac action potential by blocking the potassium channels and thus one
         or more of the potassium currents.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness indicated by correction of cardiac arrhythmias. Action results in suppression of arrhythmias dependent upon
         re-entry of potassium ions. It also prolongs the atrial and ventricular refractory period.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic atrial fibrillation and flutter.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Baseline QT/QT<sub>C</sub> interval of &gt;420 milliseconds; ventricular arrhythmias; hypersensitivity to dofetilide; concurrent administration with verapamil,
         cimetidine, trimethoprim, ketoconazole; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Atrioventricular block, bradycardia, CHF, electrolyte imbalances (e.g., hypokalemia, hypomagnesia, etc.); concurrent administration
         of potassium depleting diuretics, hepatic or renal impairment; history of moderate QT<sub>C</sub> interval prolongation; moderate to severe hypertension; recent MI or unstable angina; vascular heart disease; pregnancy (category
         C); older adults. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Atrial Fibrillation/Flutter</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Based on creatinine clearance (Cl<sub>cr</sub>) and QT<sub>c</sub> interval, if QT<sub>c</sub> increases by &gt;15% from baseline or is &gt;500 msec 23 h after initial dose. Decrease subsequent doses by 50%<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> &gt;60 mL/min: 500 mcg b.i.d.; 4060 mL/min: 250 mcg b.i.d.; 2039 mL/min: 125 mcg b.i.d.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give dofetilide if QT/QT<sub>c</sub> interval &gt;420 milliseconds (or &gt;500 milliseconds with ventricular conduction abnormalities).
         </li>
<li>Individualize doses on creatinine clearance; QT<sub>c</sub> interval is used if HR 
         </li><li>Administer only with continuous ECG monitoring.</li>
<li>Do not initiate therapy until 3 mo after withdrawal of previous antiarrhythmic therapy.</li>
<li>Do not initiate therapy until 3 mo after amiodarone has been withdrawn or plasma level is 
         </li><li>Store at 15°30° C (59°86° F); protect from moisture and humidity.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flu-like syndrome, back pain. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, insomnia. <span class="typehead">CV:</span>
<span class="speceff-life">Torsades de pointes arrhythmia,</span>
<span class="speceff-both">ventricular arrhythmias,</span>
<span class="speceff-common"></span> AV block, <span class="speceff-common">chest pain.</span>
<span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain. <span class="typehead">Respiratory:</span> Respiratory infection, dyspnea. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Dofetilide</b> levels increased by <b>verapamil,</b>
<b>cimetidine,</b>
<b>trimethoprim,</b>
<b>ketoconazole,</b>
<b>prochlorperazine,</b>
<b>megestrol;</b> do not give with drugs known to increase the QT<sub>c</sub> interval such as 	<b>bepridil,</b>
<span class="classification">phenothiazine</span>, <span class="classification">tricyclic antidepressants</span>, <span class="classification">oral macrolides</span>, other <span class="classification">antiarrhythmics</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> &gt;90% bioavailable. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> 6070% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Primarily excreted unchanged in urine. <span class="typehead">Half-Life:</span> 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG continuously during first 3 mo of therapy; then periodically.</li>
<li>Do not discharge patient until 12 h after conversion to normal sinus rhythm.</li>
<li>Lab tests: Baseline and periodic serum electrolytes (including magnesium), periodic CBC, and routine blood chemistry. Serum
            potassium must be within normal limits prior to and throughout therapy with dofetilide.
         </li>
<li>Notify physician immediately of electrolyte imbalances, especially hypokalemia and hypomagnesemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately conditions that cause potassium loss (e.g., prolonged vomiting, diarrhea, excessive sweating).</li>
<li>Do <b>
<small>NOT</small>
</b> take concurrently cimetidine, verapamil, ketoconazole, trimethoprim.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>